{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:29Z","timestamp":1791461369953,"version":"4.3.4"},"reference-count":105,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to determine if any suspected adverse drug reactions (ADRs) observed with the use of angiotensin II receptor blockers (ARBs) could be linked to either (a) their unique respective physicochemical and pharmacological profiles and (b) the recently disclosed suspected carcinogenic manufacturing contaminants found in certain sartan drug class batches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The pharmacology profiles of ARBs were data\u2010mined from the Chemical Database of bioactive molecules with drug\u2010like properties, European Molecular Biology Laboratory (ChEMBL). Suspected ADR data (from 01\/2016\u201310\/2022, inclusive) and prescribing rates of ARBs over a 5\u2010year prescribing window (from 09\/2016 to 08\/2021, inclusive) were obtained via analysis of the United Kingdom Medicines and Healthcare products Regulatory Authority (MHRA) Yellow Card drug analysis profile and Open prescribing databases, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall suspected ADRs and fatalities per 100\u2009000 prescriptions identified across the ARBs studied were found to be different between the sartan drug class members (chi\u2010squared test, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). There is a greater relative rate of reports for valsartan across all investigated organ classes of ADRs, than other ARBs, despite valsartan's more limited pharmacological profile and similar physicochemical properties to other sartans. The disparity in ADR reporting rates with valsartan <jats:italic>vs<\/jats:italic> other ARBs could be due to the dissimilarity in formulation excipients, patient factors and publicity surrounding batch contaminations, amongst others. Cancer\u2010related ADRs and fatalities per 100\u2009000 prescriptions identified across the ARBs studied are not statistically significant (chi\u2010squared test, <jats:italic>P<\/jats:italic>\u2009&gt;\u2009.05) based on the datasets used over the 5\u2010year period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No connection between ARB pharmacology and their suspected ADRs could be found. No conclusion between sartan batch contaminations and increased suspected cancer\u2010related ADRs was found.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15411","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:05:37Z","timestamp":1652940337000},"page":"4812-4827","source":"Crossref","is-referenced-by-count":23,"title":["Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions"],"prefix":"10.1111","volume":"88","author":[{"given":"Hamisha","family":"Salim","sequence":"first","affiliation":[{"name":"Medicines Safety Research Group (MSRG), School of Pharmacy University of Birmingham  Birmingham United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-5626","authenticated-orcid":false,"given":"Alan M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Medicines Safety Research Group (MSRG), School of Pharmacy University of Birmingham  Birmingham United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368\u20105031.2006.00784.x"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2003.11927893"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.118.11065"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2007.13.s8\u2010b.9"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.05.008"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2014.29"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010200868090\u201000003"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001205"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20106175.2007.06395.x"},{"key":"e_1_2_12_11_1","unstructured":"Organon Pharma (UK) Limited.COZAAR 50 mg film\u2010coated tablets SmPC\u2010(emc).Medicines.org.uk.https:\/\/www.medicines.org.uk\/emc\/product\/7799\/smpc#NUMBER. Updated December 21 2018. Accessed October 21 2021."},{"key":"e_1_2_12_12_1","unstructured":"European Medicines Agency.Diovan.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/diovan-1. Published May 31 2010. Updated May 31 2010. Accessed October 21 2021."},{"key":"e_1_2_12_13_1","unstructured":"European Medicines Agency.Aprovel.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aprovel. Published May 5 2009. Updated September 23 2013. Accessed October 21 2021."},{"key":"e_1_2_12_14_1","unstructured":"Neon Healthcare Ltd.Amias 16mg tablets SmPC\u2010(emc).Medicines.org.uk.https:\/\/www.medicines.org.uk\/emc\/product\/12851\/smpc#NUMBER. Updated July 31 2021. Accessed October 21 2021."},{"key":"e_1_2_12_15_1","unstructured":"European Medicines Agency.Micardis.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/micardis. Published May 6 2009. Updated November 6 2015. Accessed October 21 2021."},{"key":"e_1_2_12_16_1","unstructured":"Mylan.Teveten 600 mg film\u2010coated tablets SmPC\u2010(emc).Medicines.org.uk.https:\/\/www.medicines.org.uk\/emc\/product\/1346\/smpc#NUMBER. Updated April 11 2018. Accessed October 21 2021."},{"key":"e_1_2_12_17_1","unstructured":"Daiichi Sankyo UK Limited.OLMETEC film\u2010coated tablets SmPC\u2010(emc).https:\/\/www.medicines.org.uk\/emc\/product\/5572\/smpc#. Updated September 30 2020. Accessed October 21 2021."},{"key":"e_1_2_12_18_1","unstructured":"European Medicines Agency.Edarbi.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/edarbi. Published December 15 2011. Updated February 10 2021. Accessed October 21 2021."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw033.06"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976\u2010500x.120957"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619865413"},{"key":"e_1_2_12_22_1","unstructured":"SchurerM Spontaneous reporting.https:\/\/globalpharmacovigilance.tghn.org\/articles\/spontaneous-reporting\/. Published April 30 2019. Accessed November 2 2021."},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdata.2019.00025"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15015"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.867"},{"key":"e_1_2_12_26_1","unstructured":"LoweD.The sartan contamination story. In the Pipeline. January 4 2019.https:\/\/blogs.sciencemag.org\/pipeline\/archives\/2019\/01\/04\/the-sartan-contamination-story. Accessed April 12 2022."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1901657"},{"key":"e_1_2_12_28_1","unstructured":"Medicines and Healthcare products Regulatory Agency.MHRA recalls valsartan blood pressure and heart medication from pharmacies;2018.https:\/\/www.gov.uk\/government\/news\/mhra-recalls-valsartan-blood-pressure-and-heart-medication-from-pharmacies. Accessed December 3 2021."},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.9b00535"},{"key":"e_1_2_12_30_1","unstructured":"Medicines and Healthcare products Regulatory Agency.MHRA recalls contaminated irbesartan and losartan batches as precautionary measure;2021.https:\/\/www.gov.uk\/government\/news\/mhra-recalls-contaminated-irbesartan-batches-as-precautionary-measure. Accessed October 15 2021."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3855"},{"key":"e_1_2_12_32_1","unstructured":"European Medicines Agency.Update on review of valsartan medicines following detection of impurity in active substance.2018.www.ema.europa.eu\/news\/update-review-valsartan-medicines-following-detection-impurity-active-substance. Accessed April 12 2022."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12995"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41371\u2010020\u201000425\u2010z"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17521"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044494"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3851"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0129"},{"key":"e_1_2_12_39_1","unstructured":"Electronic Medicines Compendium (EMC).Medicines.org.uk.https:\/\/www.medicines.org.uk\/emc\/. Accessed October 27 2021."},{"key":"e_1_2_12_40_1","unstructured":"ChEMBL Database.Ebi.ac.uk.https:\/\/www.ebi.ac.uk\/chembl\/. Accessed October 27 2021."},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2018.09.022"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/b978\u20100\u201012\u2010417205\u20100.00015\u20108"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.603"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1039\/c1md00017a"},{"key":"e_1_2_12_45_1","unstructured":"European Medicines Agency.Edarbi assessment report.https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/edarbi-epar-public-assessment-report_en.pdf. Accessed November 3 2021."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000991"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010200262090\u201000005"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111047"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018903"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2012.693502"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017459"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703150"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.699"},{"key":"e_1_2_12_54_1","unstructured":"Open Prescribing.https:\/\/openprescribing.net\/. Accessed November 11 2021."},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911\u2010018\u20100642\u20106"},{"key":"e_1_2_12_56_1","unstructured":"Interactive Drug Analyses profiles.https:\/\/yellowcard.mhra.gov.uk\/iDAP\/. Accessed November 15 2021."},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15538"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15543"},{"key":"e_1_2_12_59_1","unstructured":"valsartan.Joint Formulary Committee.https:\/\/doi.org.ezproxye.bham.ac.uk\/10.18578\/BNF.579351575. Accessed October 27 2021."},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2006.01.013"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm1008456"},{"key":"e_1_2_12_62_1","unstructured":"Aurobindo Pharma \u2010 Milpharm Ltd.Valsartan 160 mg capsules SmPC\u2010(emc).Medicines.org.uk.https:\/\/www.medicines.org.uk\/emc\/product\/7118\/smpc#EXCIPIENTS. Updated November 9 2021. Accessed December 3 2021."},{"key":"e_1_2_12_63_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1201\/9781420026054","volume-title":"Water\u2010Insoluble Drug Formation","author":"Liu R","year":"2000"},{"key":"e_1_2_12_64_1","volume-title":"Handbook of Pharmaceutical Excipients","author":"Rowe R","year":"2010"},{"key":"e_1_2_12_65_1","unstructured":"European Medicines Agency.Background review for sodium laurilsulfate used as an excipient.https:\/\/www.ema.europa.eu\/en\/documents\/report\/background-review-sodium-laurilsulfate-used-excipient-context-revision-guideline-excipients-label_en.pdf. Published July 23 2015. Accessed December 3 2021."},{"key":"e_1_2_12_66_1","unstructured":"National Institute for Health and Care Excellence (NICE).Hypertension: Angiotensin\u2010II receptor blockers.https:\/\/cks.nice.org.uk\/topics\/hypertension\/prescribing-information\/angiotensin-ii-receptor-blockers\/. Updated April 2021. Accessed December 5 2021."},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.302"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s2468"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.4.541"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.15.32"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00239"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010021\u201000778\u20108"},{"issue":"1","key":"e_1_2_12_73_1","first-page":"62","article-title":"AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats","volume":"298","author":"Gohlke P","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872\u2010200205000\u201000026"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102377\u20109\u2010s1\u2010s3"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.10.58"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.119.005536"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.003"},{"issue":"1","key":"e_1_2_12_79_1","first-page":"47","article-title":"Olmesartan and drug\u2010induced enteropathy","volume":"39","author":"Tran TH","year":"2014","journal-title":"Pharma Therap"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz019"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3047w"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4645"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/b978\u20100\u201012\u2010387817\u20105.00007\u20108"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp060004w"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1533\/9781908818287.327"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048264"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b17\u201000174"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2013.806537"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010014\u20100239\u20107"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2000.11927719"},{"issue":"3","key":"e_1_2_12_91_1","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch T","year":"2007","journal-title":"Am Fam Physician"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.02.017"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12789"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1186\/gm405"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.06.016"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK\u201010\u2010RV\u2010094"},{"key":"e_1_2_12_97_1","volume-title":"StatPearls","author":"Fountain JH","year":"2021"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.5152\/TurkThoracJ.2018.18014"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2020.08.007"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796\u2010814"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102125.1999.00855.x"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200629050\u201000003"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200730100\u201000007"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)31163\u20107"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/235130"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.12968\/jprp.2019.1.4.182"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15411","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:54:41Z","timestamp":1692608081000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/bcp.15411"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15411","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}